All In Biotech

Drug Trial Radar · NCT04302064

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

A Randomized, Double-Blinded, Placebo-Controlled, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of ION-682884 in Healthy Japanese Participants

Last checked: Nov 20, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Apr 23, 2020

Primary completion

Sep 10, 2020

Study completion Sep 10, 2020

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Mar 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of single and potentially multiple doses of Eplontersen administered subcutaneously (SC) to healthy Japanese participants.

Conditions

  • Healthy Participants

Interventions

  • EplontersenDrug

    Eplontersen administered SC

  • PlaceboDrug

    Eplontersen-matching placebo administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by SeverityTime frame: Up to 92 days
  2. Percentage of Participants with TEAEs Potentially Related to Study DrugTime frame: Up to 92 days
  3. Percentage of Participants with Changes in Clinically Significant (CS) Laboratory Value AbnormalitiesTime frame: Up to 92 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.